LIT-927

Catalog No.S8813 Batch:S881301

Print

Technical Data

Formula

C17H13ClN2O3
Molecular Weight 328.75 CAS No. 2172879-52-4
Solubility (25°C)* In vitro DMSO 66 mg/mL (200.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.25mg/ml Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description LIT-927 is a novel neutraligand of CXCL12 with Ki value of 267 nM for inhibition of Texas red-labeled CXCL12 (CXCL12-TR) binding. It shows high selectivity toward CXCL12 vs other chemokines also involved in asthma.
Targets
CXCR4 [1] CXCL12 [1]
267 nM(Ki)
In vitro

LIT-927 is able to bind selectively CXCL12 and to inhibit CXCL12-CXCR4 interaction[1].
In vivo

In a murine model of hypereosinophilia, LIT-927 shows a large and statistically reliable inhibition of eosinophil recruitment. It inhibits allergic eosinophilic airway inflammation in mice when administered orally or locally[1].

Protocol (from reference)

Selleck's LIT-927 has been cited by 4 publications

THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer [ Nat Commun, 2023, 14(1):5534] PubMed: 37749092
THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer [ Nat Commun, 2023, 14(1):5534] PubMed: 37749092
Loss of bone morphogenetic protein signaling in fibroblasts results in CXCL12-driven serrated polyp development [ J Gastroenterol, 2022, 10.1007/s00535-022-01928-x] PubMed: 36326956
Engineer a pre-metastatic niched microenvironment to attract breast cancer cells by utilizing a 3D printed polycaprolactone/nano-hydroxyapatite osteogenic scaffold - An in vitro model system for proof of concept [ J Biomed Mater Res B Appl Biomater, 2022, 10.1002/jbm.b.35021] PubMed: 35112785

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.